Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.060 -0.020 (-1.85%)
Delayed Quote Updated: 2:50 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 264,149
Open 1.100
Bid (Size) 1.060 (9,000)
Ask (Size) 1.070 (6,100)
Prev. Close 1.080
Today's Range 1.060 - 1.100
52wk Range 1.020 - 1.950
Shares Outstanding 35,937,937
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-15.2%
-15.2%
1 Month
-3.6%
-3.6%
3 Month
-4.5%
-4.5%
6 Month
-19.7%
-19.7%
1 Year
-28.4%
-28.4%

More News

Read More
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF
Via MarketMinute
News headline image
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Thursday's session. ↗
Via Chartmill
News headline image
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
Via Benzinga
News headline image
Get insights into the top gainers and losers of Friday's after-hours session. ↗
Via Chartmill
News headline image
Pliant Therapeutics Provides Update on BEACON-IPF
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
From Pliant Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations
From Pliant Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Pliant Therapeutics, Inc. - Common Stock publicly traded?
Yes, Pliant Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Pliant Therapeutics, Inc. - Common Stock trade on?
Pliant Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Pliant Therapeutics, Inc. - Common Stock?
The ticker symbol for Pliant Therapeutics, Inc. - Common Stock is PLRX on the Nasdaq Stock Market
What is the current price of Pliant Therapeutics, Inc. - Common Stock?
The current price of Pliant Therapeutics, Inc. - Common Stock is 1.060
When was Pliant Therapeutics, Inc. - Common Stock last traded?
The last trade of Pliant Therapeutics, Inc. - Common Stock was at 10/01/26 02:50 PM ET
What is the market capitalization of Pliant Therapeutics, Inc. - Common Stock?
The market capitalization of Pliant Therapeutics, Inc. - Common Stock is 38.09M
How many shares of Pliant Therapeutics, Inc. - Common Stock are outstanding?
Pliant Therapeutics, Inc. - Common Stock has 38M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.